The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.
Taxanes, including docetaxel (DOCE), are severely neurotoxic, causing disabling peripheral neuropathy. Co-treatment with neuroprotective agents has been proposed to prevent or reverse this. Besides its hemopoietic effects, erythropoietin (EPO) has neuroprotective and neurotrophic properties and when...
| Egile Nagusiak: | , , , , , , , , , , , , , , |
|---|---|
| Formatua: | Journal article |
| Hizkuntza: | English |
| Argitaratua: |
2010
|
| _version_ | 1826291487000756224 |
|---|---|
| author | Cervellini, I Bello, E Frapolli, R Porretta-Serapiglia, C Oggioni, N Canta, A Lombardi, R Camozzi, F Roglio, I Melcangi, R D'incalci, M Lauria, G Ghezzi, P Cavaletti, G Bianchi, R |
| author_facet | Cervellini, I Bello, E Frapolli, R Porretta-Serapiglia, C Oggioni, N Canta, A Lombardi, R Camozzi, F Roglio, I Melcangi, R D'incalci, M Lauria, G Ghezzi, P Cavaletti, G Bianchi, R |
| author_sort | Cervellini, I |
| collection | OXFORD |
| description | Taxanes, including docetaxel (DOCE), are severely neurotoxic, causing disabling peripheral neuropathy. Co-treatment with neuroprotective agents has been proposed to prevent or reverse this. Besides its hemopoietic effects, erythropoietin (EPO) has neuroprotective and neurotrophic properties and when administered systemically it has a wide range of neuroprotective action in animal models of nervous system damage, including cisplatin-induced peripheral neurotoxicity. The present study investigated the effects of EPO on chemotherapy-induced peripheral neurotoxicity (CINP) by DOCE in vivo and whether it interfered with tumor growth or antitumor activity. Female Fischer rats bearing 13762 mammary carcinoma were randomly divided into four groups: untreated, treated with EPO, DOCE, or DOCE + EPO. DOCE was given once a week (5 mg/kg, i.v.) and EPO three times a week (50 microg/kg i.p.), for 4 weeks. Three other groups of rats without tumors were left untreated or given DOCE or DOCE + EPO. The rats were observed for 4 weeks after treatment. CINP and neuroprotection were evaluated by measuring nociception, electrophysiological, and biochemical parameters. EPO protected against CINP, and tumor growth in EPO-treated rats was the same as in controls. EPO significantly improved the thermal threshold, tail nerve conduction velocity, and intra-epidermal nerve fiber density. These benefits lasted through the follow-up period and EPO speeded-up spontaneous recovery after treatment withdrawal. EPO did not impair DOCE antitumor activity. Since CINP induced by DOCE reproduces the clinical utility of taxane in humans, the findings reported might provide a basis for investigating EPO as a neuroprotective agent in patients receiving therapy with DOCE. |
| first_indexed | 2024-03-07T03:00:07Z |
| format | Journal article |
| id | oxford-uuid:b0af6af4-3a18-4a24-b136-5326d9b96e33 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:00:07Z |
| publishDate | 2010 |
| record_format | dspace |
| spelling | oxford-uuid:b0af6af4-3a18-4a24-b136-5326d9b96e332022-03-27T03:58:14ZThe neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b0af6af4-3a18-4a24-b136-5326d9b96e33EnglishSymplectic Elements at Oxford2010Cervellini, IBello, EFrapolli, RPorretta-Serapiglia, COggioni, NCanta, ALombardi, RCamozzi, FRoglio, IMelcangi, RD'incalci, MLauria, GGhezzi, PCavaletti, GBianchi, RTaxanes, including docetaxel (DOCE), are severely neurotoxic, causing disabling peripheral neuropathy. Co-treatment with neuroprotective agents has been proposed to prevent or reverse this. Besides its hemopoietic effects, erythropoietin (EPO) has neuroprotective and neurotrophic properties and when administered systemically it has a wide range of neuroprotective action in animal models of nervous system damage, including cisplatin-induced peripheral neurotoxicity. The present study investigated the effects of EPO on chemotherapy-induced peripheral neurotoxicity (CINP) by DOCE in vivo and whether it interfered with tumor growth or antitumor activity. Female Fischer rats bearing 13762 mammary carcinoma were randomly divided into four groups: untreated, treated with EPO, DOCE, or DOCE + EPO. DOCE was given once a week (5 mg/kg, i.v.) and EPO three times a week (50 microg/kg i.p.), for 4 weeks. Three other groups of rats without tumors were left untreated or given DOCE or DOCE + EPO. The rats were observed for 4 weeks after treatment. CINP and neuroprotection were evaluated by measuring nociception, electrophysiological, and biochemical parameters. EPO protected against CINP, and tumor growth in EPO-treated rats was the same as in controls. EPO significantly improved the thermal threshold, tail nerve conduction velocity, and intra-epidermal nerve fiber density. These benefits lasted through the follow-up period and EPO speeded-up spontaneous recovery after treatment withdrawal. EPO did not impair DOCE antitumor activity. Since CINP induced by DOCE reproduces the clinical utility of taxane in humans, the findings reported might provide a basis for investigating EPO as a neuroprotective agent in patients receiving therapy with DOCE. |
| spellingShingle | Cervellini, I Bello, E Frapolli, R Porretta-Serapiglia, C Oggioni, N Canta, A Lombardi, R Camozzi, F Roglio, I Melcangi, R D'incalci, M Lauria, G Ghezzi, P Cavaletti, G Bianchi, R The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats. |
| title | The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats. |
| title_full | The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats. |
| title_fullStr | The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats. |
| title_full_unstemmed | The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats. |
| title_short | The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats. |
| title_sort | neuroprotective effect of erythropoietin in docetaxel induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma bearing rats |
| work_keys_str_mv | AT cervellinii theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT belloe theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT frapollir theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT porrettaserapigliac theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT oggionin theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT cantaa theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT lombardir theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT camozzif theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT roglioi theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT melcangir theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT dincalcim theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT lauriag theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT ghezzip theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT cavalettig theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT bianchir theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT cervellinii neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT belloe neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT frapollir neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT porrettaserapigliac neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT oggionin neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT cantaa neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT lombardir neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT camozzif neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT roglioi neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT melcangir neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT dincalcim neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT lauriag neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT ghezzip neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT cavalettig neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats AT bianchir neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats |